Search results for "Lymphatic"

showing 10 items of 1179 documents

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered ce…

2011

Disappearance of normal bone marrow (BM) plasma cells (PC) predicts malignant transformation of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) into symptomatic multiple myeloma (MM). The homing, behavior and survival of normal PC, but also CD34 hematopoietic stem cells (HSC), B-cell precursors, and clonal PC largely depends on their interaction with stromal cell-derived factor-1 (SDF-1) expressing, potentially overlapping BM stromal cell niches. Here, we investigate the distribution, phenotypic characteristics and competitive migration capacity of these cell populations in patients with MGUS, SMM and MM vs healthy adults (HA) aged 60 years. Our result…

AdultMalemalignant transformationCancer ResearchPathologymedicine.medical_specialtyStromal cellPlasma CellsParaproteinemiasCD34Bone Marrow CellsEnzyme-Linked Immunosorbent AssayBiologyplasma cellsImmunophenotypingImmunophenotypingCell Movementhemic and lymphatic diseasesmedicineHumansProspective StudiesCells CulturedMultiple myelomaAgedAged 80 and overB-Lymphocytesmonoclonal gammopathiesbone marrow niche competitionHematologyMiddle AgedFlow CytometryHematopoietic Stem Cellsmedicine.diseaseClone CellsHaematopoiesisLeukemiamedicine.anatomical_structureOncologyCase-Control StudiesCancer researchFemaleBone marrowMultiple MyelomaMonoclonal gammopathy of undetermined significanceLeukemia
researchProduct

Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis.

2003

To identify predictive factors of response to interferon alpha (IFN-alpha) plus ribavirin therapy in patients with chronic hepatitis C (CHC), the presence of lymphadenopathy (LyA) of the hepatoduodenal ligament and other variables were investigated. A total of 110 patients with histologically proven CHC were enrolled in this study. Ultrasound (US) was performed at the start and end of therapy and 6 months after stopping therapy. At baseline, LyA was present in 35 (43.7%) of 80 patients with alanine aminotransferase (ALT) values and grading was significantly higher than in the LyA-negative group. LyA was more frequent in nonresponders (nonR) than in relapsers (relR) or sustained responders (…

AdultMalemedicine.medical_specialtyAcoustics and UltrasonicsEnd of therapyBiophysicsAlpha interferonGastroenterologyAntiviral Agentschemistry.chemical_compoundInternal medicineRibavirinmedicineHumansUltrasound Lymphadenopathy Chronic hepatitis C Treatment Predictive factors.Radiology Nuclear Medicine and imagingProspective StudiesAlanine aminotransferaseLymph nodeLymphatic DiseasesUltrasonographyHepatitisRadiological and Ultrasound Technologybusiness.industryRibavirinInterferon-alphaHepatoduodenal ligamentHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureLogistic ModelsTreatment OutcomechemistryDrug Therapy CombinationFemaleLymphbusinessUltrasound in medicinebiology
researchProduct

Frequency and Characterization of Benign Lesions in Patients Undergoing Surgery for the Suspicion of Solid Pancreatic Neoplasm

2013

A diagnosis of benign lesions (BLs) is reported in 5% to 21% of pancreatoduodenectomies performed for neoplasms; no data for body-tail resections are available. The aims were to investigate the frequency and characterize the BLs mimicking cancer in the head and the body-tail of the pancreas.This study is a retrospective review of pancreatic specimenscollected from 2005 to 2011 in the pathology database of Mainz (Germany). Patients with final diagnosis excluding malignancy were analyzed by histology, imaging, and clinical aspects.Among 373 patients, 33 patients (8.8%) were diagnosed with a benign disease: 25 (8.4%) of 298 in the pancreatic head and 8 (10.7%) of 75 in the body-tail resections…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmenteducationSymptom assessmentChoristomaUnnecessary ProceduresAutoimmune DiseasesDiagnosis DifferentialYoung AdultPancreatectomyEndocrinologyGermanyhemic and lymphatic diseasesDiagnosis80 and overPrevalenceInternal MedicineHumansMedicineNeoplasmIn patientAgedRetrospective StudiesAged 80 and overAdolescent; Adult; Aged; Aged 80 and over; Autoimmune Diseases; Choristoma; Diagnosis Differential; Female; Germany; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Diseases; Pancreatic Neoplasms; Pancreatitis; Prevalence; Retrospective Studies; Spleen; Symptom Assessment; Unnecessary Procedures; Young AdultHepatologybusiness.industryGastroenterologyPancreatic DiseasesCancerRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryPancreatic NeoplasmsPancreatitisDifferentialPancreatectomyPancreatitisFemaleRadiologySymptom AssessmentDifferential diagnosisbusinessSpleenPancreas
researchProduct

Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series

2020

BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic ris…

AdultMalemedicine.medical_specialtyAdolescentHemophilia A HemarthrosisHemophilic arthropathyrFVIIIPharmacokineticProphylaxisHaemophilia A030204 cardiovascular system & hematologyHemophilia ARecombinant factor viii03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicineHumansChildVariable disease severityAgedRetrospective StudiesThrombotic riskFactor VIIIbusiness.industryHematologyHemarthrosisMiddle Agedmedicine.diseaseThird generationClinical PracticeTreatment OutcomeConcomitantbusiness030215 immunology
researchProduct

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoprolif…

2010

Long term immunosuppression and therapy of acute rejections result in a 20-120-fold increased risk to develop Non Hodgkin lymphoma (NHL). Since immunosuppressive therapy and immunological disorders are major risk factors for the development of NHL in the non-transplant population we aimed to analyze risk factors for PTLD in our cohort of liver transplanted (LT) patients.We analyzed retrospectively 431 patients liver transplanted between 1998 and 2008.PTLD was diagnosed in eleven of 431 patients (2.6%). PTLD, especially late PTLD, was significantly more frequent in patients who received steroids before LT (Kaplan-Meier: p0.001). Moreover PTLD in immunocompromised patients with preoperative s…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationAutoimmune hepatitisKaplan-Meier EstimateLiver transplantationGastroenterologyYoung AdultPostoperative ComplicationsRisk Factorshemic and lymphatic diseasesInternal medicinePreoperative CareInternal MedicinemedicineCadaverHumansProspective cohort studyeducationChildAgedProportional Hazards ModelsRetrospective StudiesHepatitiseducation.field_of_studybusiness.industryLymphoma Non-HodgkinRetrospective cohort studyImmunosuppressionMiddle Agedmedicine.diseaseTissue DonorsLymphomaLiver TransplantationHepatitis Autoimmunesurgical procedures operativeImmunologyMultivariate AnalysisFemaleSteroidsbusinessImmunosuppressive AgentsEuropean journal of internal medicine
researchProduct

Memory B Cell Subpopulations in the Aged

2006

The literature on immunosenescence has focused mainly on T cell impairment. With the aim of gaining insight into B cell immunosenescence, the authors investigated the serum IgD levels in 24 young and 21 old people and analyzed their relationship with the number of CD19 CD27 memory cells. Serum IgD were quantified by the use of radial immunodiffusion and the lymphocyte population CD19 CD27 was identified by a FACScan flow cytometer. Serum IgD levels were significantly lower (p 0.0001) in old subjects, and the percentage of CD19 CD27 lymphocytes were significantly increased (p 0.01) in old subjects. Finally, a significant negative correlation was found (p 0.01) between serum concentrations of…

AdultMalemedicine.medical_specialtyAgingLymphocyteT cellPopulationAntigens CD19B-Lymphocyte Subsetschemical and pharmacologic phenomenaimmunosenescence memory B cells IgD CD27Immunoglobulin DCD19immune system diseaseshemic and lymphatic diseasesInternal medicinemedicineHumanseducationMemory B cellB cellAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studybiologyhemic and immune systemsImmunosenescenceImmunoglobulin DTumor Necrosis Factor Receptor Superfamily Member 7Endocrinologymedicine.anatomical_structureImmunologybiology.proteinFemaleGeriatrics and GerontologyImmunologic Memory
researchProduct

Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous…

1998

Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) and cyclophosphamide (CY). We studied the pharmacokinetics of cyclophosphamide on hemodialysis and compared clinical parameters including time to engraftment and toxicity with parameters of a patient with normal renal function who also received an unrelated marrow as treatment for CML in first chronic phase. Our results suggest that TBI/CY is a suitable conditioning regimen for…

AdultMalemedicine.medical_specialtyAllogeneic transplantationTransplantation ConditioningCyclophosphamidemedicine.medical_treatmentGastroenterologyRenal Dialysishemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansTransplantation HomologousAntineoplastic Agents AlkylatingCyclophosphamidePreparative RegimenBone Marrow TransplantationTransplantationChemotherapyNephrosclerosisbusiness.industryHematologyTotal body irradiationmedicine.diseaseSurgeryCase-Control StudiesKidney Failure ChronicHemodialysisbusinessWhole-Body Irradiationmedicine.drugKidney diseaseChronic myelogenous leukemiaBone marrow transplantation
researchProduct

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findin…

2018

Patients with primary refractory or relapsed acute myeloid leukemia (RR-AML) have very poor prognosis. Due to limited treatment options, some patients are treated with hypomethylating agents (HMAs) due to their tolerability. Little is known about the role of allogeneic hematopoietic stem cell transplantation (HSCT) following HMA therapy in this setting. We retrospectively analyzed an international cohort of 655 RR-AML patients who received HMA therapy to study patterns and outcomes with HSCT. Only 37 patients (5.6%) patients underwent HSCT after HMA therapy. The conditioning regimen was myeloablative in 57% and nonmyeloablative in 43%. Patients received matched unrelated donor, matched sibl…

AdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticTransplantation ConditioningSurvivalmedicine.medical_treatmentSalvage therapyGraft vs Host DiseaseHypomethylating agentsHematopoietic stem cell transplantationTransplant03 medical and health sciences0302 clinical medicineRefractoryAMLimmune system diseasesInternal medicinehemic and lymphatic diseasesmedicineHumansTransplantation HomologousSurvival analysisAgedRetrospective StudiesSalvage TherapyTransplantationAML; Hypomethylating agents; Survival; Transplant; Adult; Aged; Antimetabolites Antineoplastic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation Homologousbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle AgedSurvival AnalysisLeukemia Myeloid Acutesurgical procedures operativeTolerability030220 oncology & carcinogenesisCohortFemaleTransplantation Conditioningbusiness030215 immunology
researchProduct

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis

2014

Abstract Introduction Splanchnic vein thrombosis (SVT) is a serious complication in patients with paroxysmal nocturnal hemoglobinuria (PNH). Mutant PNH clones can be associated with an increased risk of SVT even in the absence of overt disease, but their prevalence in non-selected SVT patients remains unknown. Materials and Methods Patients with objective diagnosis of SVT and without known PNH were tested for the presence of PNH clone using high-sensitivity flow cytometric analysis. Results A total of 202 SVT patients were eligible, 58.4% were males, mean age was 54.6 years (range 17–94), site of thrombosis was portal in 103 patients, mesenteric in 67, splenic in 37, and supra-hepatic in 10…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentParoxysmalHemoglobinuria ParoxysmalHemoglobinuriaGastroenterologyYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicine80 and overmedicineHumansMyeloproliferative neoplasmAgedAged 80 and overVenous Thrombosisbusiness.industryMedicine (all)Splanchnic vein thrombosisHematologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsThrombosisAdolescent; Adult; Aged; Aged 80 and over; Cross-Sectional Studies; Female; Hematopoietic Stem Cells; Hemoglobinuria Paroxysmal; Humans; Male; Middle Aged; Risk Factors; Venous Thrombosis; Young Adult; Hematology; Medicine (all)SurgeryPortal vein thrombosisVenous thrombosisSettore MED/15 - MALATTIE DEL SANGUECross-Sectional StudiesSplanchnic vein thrombosisParoxysmal nocturnal hemoglobinuriaFemaleHemoglobinuriabusiness
researchProduct